Semax, an analog of ACTH (4-7) , regulates expression of immune response genes during ischemic brain injury in rats.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model (transcriptomic profiling in rats)
PubMed 28255762 · doi:10.1007/s00438-017-1297-1
What was done
Researchers performed genome-wide biochip transcriptome analysis of cerebral cortex tissue from rats subjected to focal cerebral ischemia and treated with either Semax (a synthetic peptide composed of an ACTH(4-7) analog and Pro-Gly-Pro) or Pro-Gly-Pro (PGP) alone. Differentially expressed genes and associated signaling pathways were analyzed using bioinformatics software (Ingenuity iReport).
What was found
The abstract reports no numerical values, fold-changes, or sample sizes. Semax treatment predominantly altered immune response pathways, enhancing antigen presentation signaling, augmenting interferon signaling, and increasing expression of the gene encoding the immunoglobulin heavy chain. It also altered cytokine, stress response, and ribosomal protein-encoding genes. Treatment with PGP alone attenuated immune activity and suppressed central nervous system neurotransmission pathways.
Why it matters
These findings suggest that the neuroprotective action of Semax in ischemic stroke models may be mediated through modulation of neuroimmune signaling pathways rather than purely direct neuronal mechanisms.
Limits
The study was conducted in a rat model of cerebral ischemia, which may not translate directly to human ischemic stroke. The abstract provides no quantitative data, effect sizes, statistical thresholds, dosage, or sample size (n). Functional neurological outcomes and survival were not reported.
Cited by
- supports Semax is a 7-amino-acid peptide studied in Russia that demonstrated improved outcomes following traumatic brain injury and stroke.